Analyst consensus rating
Akebia Therapeutics Analyst Rating: Buy
AKBA is rated Buy by 5 analysts with a $3.80 target. As of 2026-08-28.
Direct answer
Akebia Therapeutics's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.80.
Forecast evidence checked August 28, 2026.
Get free Akebia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.88
- Average price target
- $3.80
- High price target
- $6.00
- Low price target
- $1.00
- Low target gap
- +13.9%
- Target upside
- +332.9%
- High target gap
- +583.4%
- Target range width
- 569.5%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Akebia Therapeutics?
Akebia Therapeutics has a verified Buy consensus. The same dataset has an average price target of $3.80.
How far are Akebia Therapeutics's low and high targets from the recorded price?
The low target implies +13.9%, while the high target implies +583.4%.
How many analysts are included in Akebia Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Akebia Therapeutics's target upside or downside calculated?
The average target of $3.80 is divided by the recorded price of $0.88, then one is subtracted to produce +332.9%. This does not guarantee a future return.
When was Akebia Therapeutics's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.